PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
04-Jun-2024 FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol Intoxication AccessWire
04-Jun-2024 Theralase(R) Technology Effective in Virus Inactivation AccessWire
04-Jun-2024 Diversity and Inclusion Interest Group Survey PM Society
04-Jun-2024 The Sustained, Slow Declining, Blood Concentration Profile of NV-387 Enables Infrequent Dosing for Strong Antiviral Effect AccessWire
04-Jun-2024 Zomedica Increases Manufacturing Capacity with Expansion of its Roswell, Georgia Facility; Can Support Production to Five times Current Levels AccessWire
04-Jun-2024 Amphastar Announces Additional $50 Million Increase to its Share Buyback Program AccessWire
04-Jun-2024 Bio-Sourcing and Afrigen Biologics partner on groundbreaking biomanufacturing platform to improve access to biotherapeutics in South Africa Andrew Lloyd Associates
04-Jun-2024 Lynred introduces two infrared imaging detectors for Optical Gas Imaging applications Andrew Lloyd Associates
04-Jun-2024 Cannovum Cannabis AG: Cash capital increase from authorized capital with subscription rights Cannovum Cannabis AG
04-Jun-2024 APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management APONTIS PHARMA AG
04-Jun-2024 Data4Cure to Present at the BIO International Convention 2024 AccessWire
03-Jun-2024 Regulatory Expert Appointed to Lead West Coast US Client Engagement for G&L Healthcare Advisors Newswire
03-Jun-2024 Regulatory Expert Appointed to Lead West Coast US Client Engagement for G&L Healthcare Advisors AccessWire
03-Jun-2024 ENCOURAGING NEW DATA PRESENTED ON KITE’S YESCARTA (AXICABTAGENE CILOLECUEL) FOR RELAPSED/REFRACTORY CENTRAL NERVOUS SYSTEM LYMPHOMA Kite, a Gilead Company
03-Jun-2024 Lundbeck presents innovative first in human trial design of Lu AG13909 for potential treatment of congenital adrenal hyperplasia H. Lundbeck A/S
03-Jun-2024 Grey Wolf Therapeutics Presents First Clinical Data for GRWD5769, a First-in-Class ERAP1 Inhibitor, at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting Grey Wolf Therapeutics
03-Jun-2024 TMC welcomes Joe Lopez as Chief Financial Officer (CFO) to enhance corporate C-level team TMC Pharma Services Ltd
03-Jun-2024 Qlucore starts project after receiving prestigious EU grant to advance personalized cancer treatment Qlucore
03-Jun-2024 STORM Therapeutics Presented Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024 STORM Therapeutics
03-Jun-2024 HUTCHMED Highlights Publication of Phase III FRUTIGA Results in Nature Medicine HUTCHMED